The Priority Review

Category

Clinical trials

Trial starts, readouts, holds and designs.

267 stories · page 13 of 23

Stories

  1. Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143

    Johnson & Johnson said that in a Phase 1 study of JNJ-6143, 75 percent (12 of 16) of patients with measurable disease achieved a confirmed complete or partial response. The company also noted that 77 percent of patients at the 50-mg dose had a confirmed PSA reduction of at least 50 percent, with 48 percent achieving reductions of at least 90 percent.

  2. Mitapivat shows haemoglobin response in sickle cell disease trial

    In the RISE UP phase 3 trial, 56 (41%) of 138 patients on mitapivat achieved a haemoglobin response versus 2 (3%) of 69 on placebo, an adjusted difference of 38% (95% CI 29-47). The annualised rate of pain crises was 2·6 for mitapivat and 3·1 for placebo (p=0·1213).

  3. Nivolumab plus relatlimab plus chemo vs nivolumab plus chemo in NSCLC

    The authors reported that the primary endpoint of objective response rate was not met (51.3% versus 45.0%). In the PD-L1 ≥1% nonsquamous subgroup, a trend toward improved clinical benefit was seen (ORR 58.0% versus 39.6%; PFS HR 0.68).

  4. Lilly reports 79% response rate for Sofe-M in platinum-sensitive ovarian cancer

    The Phase 1 study of sofetabart mipitecan (Sofe-M) plus bevacizumab in 29 patients with measurable disease reported a confirmed objective response rate of 79.3% (23/29) and a disease control rate of 100%. The most common grade ≥3 adverse events were neutropenia (42%) and anemia (24%), with 6% of patients discontinuing treatment due to an adverse event.

  5. 64.0 percent had a pathological complete response on pembrolizumab, 54.7 percent on placebo, in TNBC

    In KEYNOTE-522, 64.0 percent on pembrolizumab plus chemotherapy had a pathological complete response, against 54.7 percent on placebo plus chemotherapy. The study record now holds final event-free survival and overall survival results for 1,174 participants.

  6. 14.8 vs 7.8 months median overall survival, brentuximab vedotin combination vs placebo, in DLBCL

    In ECHELON-3, median overall survival was 14.8 months with brentuximab vedotin plus lenalidomide and rituximab and 7.8 months with placebo plus the same two drugs. The study record now holds the primary outcome for 230 participants with relapsed or refractory DLBCL.

  7. Vertex registers Phase 3b study of Povetacicept vs Sibeprenlimab in Immunoglobulin A Nephropathy

    Vertex Pharmaceuticals Incorporated has registered a Phase 3b, open-label, single-arm study to evaluate participant experience with Povetacicept injection via autoinjector compared to Sibeprenlimab injection via prefilled syringe in adults with Immunoglobulin A Nephropathy. The study plans to enroll 40 participants, with a start date of October 23, 2026 and primary completion date of December 12, 2027.

  8. Hoffmann-La Roche registers Phase III trial of enicepatide versus tirzepatide in type 2 diabetes

    The study, led by Hoffmann-La Roche with Chugai Pharmaceutical as collaborator, plans to enroll 948 participants and begin on December 1, 2026. It will evaluate the efficacy and safety of enicepatide, a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor (GLP-1/GIP) receptor agonist (RA), compared with tirzepatide in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on oral glucose-lowering medications.

  9. Sanofi registers Phase 3 trial of combination SARS-CoV-2 and influenza vaccine in older adults

    The study, led by Sanofi, plans to enroll an estimated 6000 participants aged 60 and older to assess the safety and immunogenicity of a combined SARS-CoV-2 recombinant spike and high-dose inactivated influenza vaccine with Matrix-M adjuvant. It is planned to begin on November 9, 2026, with primary completion expected on December 28, 2027.

  10. Pfizer registers Phase 3 trial of atirmociclib plus giredestrant in ER+ HER2- early breast cancer

    The study plans to enroll 3800 participants and randomize them 1:1 to receive atirmociclib plus giredestrant or placebo plus giredestrant. It is scheduled to begin on December 1, 2026, with a primary completion date of April 13, 2032.

  11. ScandiBio registers Phase 3 trial of CMA2 in gout

    The study plans to enroll 336 participants and is expected to start in October 2026, with primary completion projected for February 2027. This will be a randomised, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of Combined Metabolic Activator (CMA2) including N-acetyl-L-cysteine, L-carnitine-L-tartrate, nicotinamide, and L-serine versus placebo.

  12. Merck posts results of Phase III KEYNOTE-522 trial in triple negative breast cancer

    The study enrolled 1,174 participants and compared pembrolizumab plus chemotherapy to placebo plus chemotherapy as neoadjuvant therapy, followed by pembrolizumab or placebo as adjuvant therapy. Results were first posted on ClinicalTrials.gov on October 22, 2026.